Measuring Health-Related Quality of Life for Patients with Diabetic Retinopathy

Note moyenne 0
( 0 avis fournis par GoodReads )
 
9781503222212: Measuring Health-Related Quality of Life for Patients with Diabetic Retinopathy
Présentation de l'éditeur :

Diabetic retinopathy (DR) is a leading cause of vision loss in the United States and occurs as a result of pathologic changes of the retinal vasculature. In 2005–2008, the estimated crude prevalence among Americans over the age of 40 with diabetes was 28.5 percent. Although the prevalence of vision-threatening DR is approximately 4.4 percent, the number of affected Americans 40 years or older is expected to triple from 1.2 million in 2005 to 3.4 million in 2050. The prevalence and severity of DR increases with the duration of diabetes; however, it is inversely correlated to glycemic and blood pressure control. Moderate vision loss is most commonly related to retinal leakage within the macula, while severe vision loss usually occurs as a result of neovascularization (proliferative diabetic retinopathy; PDR) with subsequent hemorrhage or fibrosis. Early identification and treatment of DR is important since treatment is both cost-effective and reduces vision loss. The American Academy of Ophthalmologists, the American Optometric Association, and the American Diabetes Association recommend an annual dilated eye examination for all people with diabetes, and more frequent eye examinations for people with known DR. Other researchers argue that the frequency of examinations should be stratified to an individual’s risk of progression and vision loss. The mainstay of DR treatment is aimed at reducing the risk of onset and limiting the progression of the disease. Therefore, retinal assessments should be performed on a regular basis to determine the presence and degree of DR, glycemic control should be optimized, and known risk factors such as blood pressure, dyslipidemia, elevated cholesterol, renal disease and abdominal obesity should be controlled. Direct ocular therapy should be prescribed when indicated, while vision rehabilitation and low vision aids should to be used to maximize vision if there is a loss. Until recently, the primary treatment for DR has been focal or grid laser of the retina. Serial intravitreal injections of triamcinolone have been introduced as a treatment option as they have been shown to be effective at reducing diabetic macular edema (DME); however, their use is becoming less common due to significant adverse effects including elevated intraocular pressure and cataract formation. Ranibizumab and becvacizumab are being used with increasing frequency for the treatment of DME; however they have not yet been approved for use in this condition by the Food and Drug Administration. The recommended treatment of PDR remains panretinal photocoagulation16 with vitrectomy surgery performed when necessary. It is important to note that treatment of DR is not always aimed at restoration of pre-disease visual acuity, but rather at limiting further deterioration. Patients may report a decrease in visual acuity immediately after therapy, which may manifest in low initial perceptions of treatment satisfaction. However, results from the Early Treatment Diabetic Retinopathy Study demonstrate that early treatment with either panretinal photocoagulation or vitrectomy prevents long-term disability due to blindness. Diabetic patients with retinopathy have reported that vision loss impacts multiple areas of well-being including: independence, mobility, leisure, and self-care. Additionally, DR has been found to impair functioning and overall health-related quality of life (HRQL).

Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.

Acheter neuf Afficher le livre
EUR 22,04

Autre devise

Frais de port : Gratuit
De Royaume-Uni vers Etats-Unis

Destinations, frais et délais

Ajouter au panier

Meilleurs résultats de recherche sur AbeBooks

1.

Agency for Healthcare Resea And Quality, U S Department of Healt Human Services
Edité par Createspace, United States (2014)
ISBN 10 : 1503222217 ISBN 13 : 9781503222212
Neuf(s) Paperback Quantité : 10
impression à la demande
Vendeur
The Book Depository
(London, Royaume-Uni)
Evaluation vendeur
[?]

Description du livre Createspace, United States, 2014. Paperback. État : New. 279 x 216 mm. Language: English . Brand New Book ***** Print on Demand *****.Diabetic retinopathy (DR) is a leading cause of vision loss in the United States and occurs as a result of pathologic changes of the retinal vasculature. In 2005-2008, the estimated crude prevalence among Americans over the age of 40 with diabetes was 28.5 percent. Although the prevalence of vision-threatening DR is approximately 4.4 percent, the number of affected Americans 40 years or older is expected to triple from 1.2 million in 2005 to 3.4 million in 2050. The prevalence and severity of DR increases with the duration of diabetes; however, it is inversely correlated to glycemic and blood pressure control. Moderate vision loss is most commonly related to retinal leakage within the macula, while severe vision loss usually occurs as a result of neovascularization (proliferative diabetic retinopathy; PDR) with subsequent hemorrhage or fibrosis. Early identification and treatment of DR is important since treatment is both cost-effective and reduces vision loss. The American Academy of Ophthalmologists, the American Optometric Association, and the American Diabetes Association recommend an annual dilated eye examination for all people with diabetes, and more frequent eye examinations for people with known DR. Other researchers argue that the frequency of examinations should be stratified to an individual s risk of progression and vision loss. The mainstay of DR treatment is aimed at reducing the risk of onset and limiting the progression of the disease. Therefore, retinal assessments should be performed on a regular basis to determine the presence and degree of DR, glycemic control should be optimized, and known risk factors such as blood pressure, dyslipidemia, elevated cholesterol, renal disease and abdominal obesity should be controlled. Direct ocular therapy should be prescribed when indicated, while vision rehabilitation and low vision aids should to be used to maximize vision if there is a loss. Until recently, the primary treatment for DR has been focal or grid laser of the retina. Serial intravitreal injections of triamcinolone have been introduced as a treatment option as they have been shown to be effective at reducing diabetic macular edema (DME); however, their use is becoming less common due to significant adverse effects including elevated intraocular pressure and cataract formation. Ranibizumab and becvacizumab are being used with increasing frequency for the treatment of DME; however they have not yet been approved for use in this condition by the Food and Drug Administration. The recommended treatment of PDR remains panretinal photocoagulation16 with vitrectomy surgery performed when necessary. It is important to note that treatment of DR is not always aimed at restoration of pre-disease visual acuity, but rather at limiting further deterioration. Patients may report a decrease in visual acuity immediately after therapy, which may manifest in low initial perceptions of treatment satisfaction. However, results from the Early Treatment Diabetic Retinopathy Study demonstrate that early treatment with either panretinal photocoagulation or vitrectomy prevents long-term disability due to blindness. Diabetic patients with retinopathy have reported that vision loss impacts multiple areas of well-being including: independence, mobility, leisure, and self-care. Additionally, DR has been found to impair functioning and overall health-related quality of life (HRQL). N° de réf. du libraire APC9781503222212

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 22,04
Autre devise

Ajouter au panier

Frais de port : Gratuit
De Royaume-Uni vers Etats-Unis
Destinations, frais et délais

2.

And Quality, Agency for Healthcare Resea
Edité par Createspace Independent Pub (2014)
ISBN 10 : 1503222217 ISBN 13 : 9781503222212
Neuf(s) Quantité : > 20
impression à la demande
Vendeur
PBShop
(Wood Dale, IL, Etats-Unis)
Evaluation vendeur
[?]

Description du livre Createspace Independent Pub, 2014. PAP. État : New. New Book.Shipped from US within 10 to 14 business days.THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. N° de réf. du libraire IP-9781503222212

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 18,70
Autre devise

Ajouter au panier

Frais de port : EUR 3,67
Vers Etats-Unis
Destinations, frais et délais

3.

Agency for Healthcare Resea And Quality, U S Department of Healt Human Services
Edité par Createspace, United States (2014)
ISBN 10 : 1503222217 ISBN 13 : 9781503222212
Neuf(s) Paperback Quantité : 10
impression à la demande
Vendeur
The Book Depository US
(London, Royaume-Uni)
Evaluation vendeur
[?]

Description du livre Createspace, United States, 2014. Paperback. État : New. 279 x 216 mm. Language: English . Brand New Book ***** Print on Demand *****. Diabetic retinopathy (DR) is a leading cause of vision loss in the United States and occurs as a result of pathologic changes of the retinal vasculature. In 2005-2008, the estimated crude prevalence among Americans over the age of 40 with diabetes was 28.5 percent. Although the prevalence of vision-threatening DR is approximately 4.4 percent, the number of affected Americans 40 years or older is expected to triple from 1.2 million in 2005 to 3.4 million in 2050. The prevalence and severity of DR increases with the duration of diabetes; however, it is inversely correlated to glycemic and blood pressure control. Moderate vision loss is most commonly related to retinal leakage within the macula, while severe vision loss usually occurs as a result of neovascularization (proliferative diabetic retinopathy; PDR) with subsequent hemorrhage or fibrosis. Early identification and treatment of DR is important since treatment is both cost-effective and reduces vision loss. The American Academy of Ophthalmologists, the American Optometric Association, and the American Diabetes Association recommend an annual dilated eye examination for all people with diabetes, and more frequent eye examinations for people with known DR. Other researchers argue that the frequency of examinations should be stratified to an individual s risk of progression and vision loss. The mainstay of DR treatment is aimed at reducing the risk of onset and limiting the progression of the disease. Therefore, retinal assessments should be performed on a regular basis to determine the presence and degree of DR, glycemic control should be optimized, and known risk factors such as blood pressure, dyslipidemia, elevated cholesterol, renal disease and abdominal obesity should be controlled. Direct ocular therapy should be prescribed when indicated, while vision rehabilitation and low vision aids should to be used to maximize vision if there is a loss. Until recently, the primary treatment for DR has been focal or grid laser of the retina. Serial intravitreal injections of triamcinolone have been introduced as a treatment option as they have been shown to be effective at reducing diabetic macular edema (DME); however, their use is becoming less common due to significant adverse effects including elevated intraocular pressure and cataract formation. Ranibizumab and becvacizumab are being used with increasing frequency for the treatment of DME; however they have not yet been approved for use in this condition by the Food and Drug Administration. The recommended treatment of PDR remains panretinal photocoagulation16 with vitrectomy surgery performed when necessary. It is important to note that treatment of DR is not always aimed at restoration of pre-disease visual acuity, but rather at limiting further deterioration. Patients may report a decrease in visual acuity immediately after therapy, which may manifest in low initial perceptions of treatment satisfaction. However, results from the Early Treatment Diabetic Retinopathy Study demonstrate that early treatment with either panretinal photocoagulation or vitrectomy prevents long-term disability due to blindness. Diabetic patients with retinopathy have reported that vision loss impacts multiple areas of well-being including: independence, mobility, leisure, and self-care. Additionally, DR has been found to impair functioning and overall health-related quality of life (HRQL). N° de réf. du libraire APC9781503222212

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 22,48
Autre devise

Ajouter au panier

Frais de port : Gratuit
De Royaume-Uni vers Etats-Unis
Destinations, frais et délais

4.

U. S. Department of Health and Human Services
Edité par CreateSpace Independent Publishing Platform
ISBN 10 : 1503222217 ISBN 13 : 9781503222212
Neuf(s) Paperback Quantité : 20
impression à la demande
Vendeur
BuySomeBooks
(Las Vegas, NV, Etats-Unis)
Evaluation vendeur
[?]

Description du livre CreateSpace Independent Publishing Platform. Paperback. État : New. This item is printed on demand. Paperback. 150 pages. Dimensions: 11.0in. x 8.5in. x 0.3in.Diabetic retinopathy (DR) is a leading cause of vision loss in the United States and occurs as a result of pathologic changes of the retinal vasculature. In 20052008, the estimated crude prevalence among Americans over the age of 40 with diabetes was 28. 5 percent. Although the prevalence of vision-threatening DR is approximately 4. 4 percent, the number of affected Americans 40 years or older is expected to triple from 1. 2 million in 2005 to 3. 4 million in 2050. The prevalence and severity of DR increases with the duration of diabetes; however, it is inversely correlated to glycemic and blood pressure control. Moderate vision loss is most commonly related to retinal leakage within the macula, while severe vision loss usually occurs as a result of neovascularization (proliferative diabetic retinopathy; PDR) with subsequent hemorrhage or fibrosis. Early identification and treatment of DR is important since treatment is both cost-effective and reduces vision loss. The American Academy of Ophthalmologists, the American Optometric Association, and the American Diabetes Association recommend an annual dilated eye examination for all people with diabetes, and more frequent eye examinations for people with known DR. Other researchers argue that the frequency of examinations should be stratified to an individuals risk of progression and vision loss. The mainstay of DR treatment is aimed at reducing the risk of onset and limiting the progression of the disease. Therefore, retinal assessments should be performed on a regular basis to determine the presence and degree of DR, glycemic control should be optimized, and known risk factors such as blood pressure, dyslipidemia, elevated cholesterol, renal disease and abdominal obesity should be controlled. Direct ocular therapy should be prescribed when indicated, while vision rehabilitation and low vision aids should to be used to maximize vision if there is a loss. Until recently, the primary treatment for DR has been focal or grid laser of the retina. Serial intravitreal injections of triamcinolone have been introduced as a treatment option as they have been shown to be effective at reducing diabetic macular edema (DME); however, their use is becoming less common due to significant adverse effects including elevated intraocular pressure and cataract formation. Ranibizumab and becvacizumab are being used with increasing frequency for the treatment of DME; however they have not yet been approved for use in this condition by the Food and Drug Administration. The recommended treatment of PDR remains panretinal photocoagulation16 with vitrectomy surgery performed when necessary. It is important to note that treatment of DR is not always aimed at restoration of pre-disease visual acuity, but rather at limiting further deterioration. Patients may report a decrease in visual acuity immediately after therapy, which may manifest in low initial perceptions of treatment satisfaction. However, results from the Early Treatment Diabetic Retinopathy Study demonstrate that early treatment with either panretinal photocoagulation or vitrectomy prevents long-term disability due to blindness. Diabetic patients with retinopathy have reported that vision loss impacts multiple areas of well-being including: independence, mobility, leisure, and self-care. Additionally, DR has been found to impair functioning and overall health-related quality of life (HRQL). This item ships from La Vergne,TN. Paperback. N° de réf. du libraire 9781503222212

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 22,72
Autre devise

Ajouter au panier

Frais de port : EUR 3,64
Vers Etats-Unis
Destinations, frais et délais

5.

And Quality, Agency for Healthcare Resea
Edité par Createspace Independent Pub (2014)
ISBN 10 : 1503222217 ISBN 13 : 9781503222212
Neuf(s) Quantité : > 20
impression à la demande
Vendeur
Books2Anywhere
(Fairford, GLOS, Royaume-Uni)
Evaluation vendeur
[?]

Description du livre Createspace Independent Pub, 2014. PAP. État : New. New Book. Delivered from our US warehouse in 10 to 14 business days. THIS BOOK IS PRINTED ON DEMAND.Established seller since 2000. N° de réf. du libraire IP-9781503222212

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 16,22
Autre devise

Ajouter au panier

Frais de port : EUR 10,41
De Royaume-Uni vers Etats-Unis
Destinations, frais et délais